Nevertheless, the antigen combination of EpCAM and CD147, successfully detected in vivo derived CD147+EpCAM+ taMPs and their median values significantly increased in cancer patients by an average of 4.8 fold (Figure 1B and Table 1) across all investigated tumour entities. This evidence concerns the gene EPCAM and neoplasm.